Takeda Pharmaceutical Net Income 2007-2018 | TAK

Takeda Pharmaceutical annual/quarterly net income history and growth rate from 2007 to 2018. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • Takeda Pharmaceutical net income for the quarter ending June 30, 2018 was $0.720B, a 138.04% decline year-over-year.
  • Takeda Pharmaceutical net income for the twelve months ending June 30, 2018 was $3.150B, a 373.79% decline year-over-year.
  • Takeda Pharmaceutical annual net income for 2017 was $1.069B, a 60.65% increase from 2016.
  • Takeda Pharmaceutical annual net income for 2016 was $0.665B, a 150.16% decline from 2015.
  • Takeda Pharmaceutical annual net income for 2015 was $-1.327B, a 224.37% decline from 2014.
Takeda Pharmaceutical Annual Net Income
(Millions of US $)
2017 $1,069
2016 $665
2015 $-1,327
2014 $1,067
2013 $1,588
2012 $1,577
2011 $2,986
2010 $3,202
2009 $2,392
2008 $3,555
2007 $2,846
2006 $2,677
Takeda Pharmaceutical Quarterly Net Income
(Millions of US $)
Q1 2018 $720
Q1 2017 $1,303
Q1 2016 $926
Q1 2015 $202
Q4 2015 $-1,892
Q3 2014 $156
Q2 2014 $260
Q1 2014 $326
Q4 2014 $-43
Q3 2013 $457
Q2 2013 $360
Q1 2013 $296
Q4 2013 $462
Q3 2012 $236
Q2 2012 $409
Q1 2012 $1,119
Q4 2012 $-460
Q3 2011 $322
Q2 2011 $775
Q4 2011 $394
Q4 2010 $426
Q2 2009 $-1
Q4 2009 $705
Q4 2008 $-922
Q4 2007 $583
Q4 2006 $275
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $31.357B $15.988B
Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company, engaged in manufacturing, marketing, and importing/exporting pharmaceutical drugs. Takeda's core business comprise of ethical drugs and its portfolio includes lansoprazole for the treatment of peptic ulcers, leuprolide acetate for the treatment of prostate cancer and endometriosis, pioglitazone hydrocholoride for the treatment of diabetes, and candesartan cilexetil for the treatment of hypertension. The Company promotes enhancing R&D pipeline, while concentrating its management resources to the four core therapeutic areas: lifestyle-related diseases, oncology and urological diseases, central nervous system disease and gastroenterological diseases. It operates in two segments- Ethical drug business and Consumer healthcare business. Consumer healthcare business provides Alinamin (vitamin B1 derivative preparations, etc.), Benza (cold remedies). Takeda Pharmaceutical Company Limited is headquartered in Osaka, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $40.747B 27.90
Grifols (GRFS) Spain $13.036B 15.80
Ionis Pharmaceuticals (IONS) United States $8.015B 0.00
Neurocrine Biosciences (NBIX) United States $7.953B 1754.00
Tilray (TLRY) United States $7.721B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $7.721B 11.08
Nektar Therapeutics (NKTR) United States $7.706B 11.05
Loxo Oncology (LOXO) United States $7.154B 0.00
Sage Therapeutics (SAGE) United States $6.186B 0.00
United Therapeutics (UTHR) United States $5.010B 8.19
Catalent (CTLT) United States $4.953B 20.77
FibroGen (FGEN) United States $4.173B 0.00
TESARO (TSRO) United States $4.121B 0.00
Impax Laboratories (AMRX) United States $3.863B 20.54
Taro Pharmaceutical Industries (TARO) Israel $3.599B 13.32
USANA Health Sciences (USNA) United States $2.829B 24.08
Endo (ENDP) Ireland $2.160B 3.31
Heron Therapeutics (HRTX) United States $2.082B 0.00
Ironwood Pharmaceuticals (IRWD) United States $2.007B 0.00
Aerie Pharmaceuticals (AERI) United States $1.946B 0.00
Xencor (XNCR) United States $1.940B 0.00
Zogenix (ZGNX) United States $1.826B 0.00
Corcept Therapeutics (CORT) United States $1.814B 26.63
Madrigal Pharmaceuticals (MDGL) United States $1.771B 0.00
PTC Therapeutics (PTCT) United States $1.763B 0.00
Portola Pharmaceuticals (PTLA) United States $1.657B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.536B 207.56
Theravance Biopharma (TBPH) Cayman Islands $1.488B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.472B 20.71
Arrowhead Pharmaceuticals (ARWR) United States $1.352B 0.00
TherapeuticsMD (TXMD) United States $1.220B 0.00
Esperion Therapeutics (ESPR) United States $1.156B 0.00
Spectrum Pharmaceuticals (SPPI) United States $1.110B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.968B 0.00
Tricida (TCDA) United States $0.951B 0.00
ImmunoGen (IMGN) United States $0.786B 0.00
Radius Health (RDUS) United States $0.740B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.652B 0.00
ChemoCentryx (CCXI) United States $0.613B 48.56
Karyopharm Therapeutics (KPTI) United States $0.603B 0.00
Siga Technologies (SIGA) United States $0.594B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.569B 0.00
Flexion Therapeutics (FLXN) United States $0.532B 0.00
Collegium Pharmaceutical (COLL) United States $0.520B 0.00
Forty Seven (FTSV) United States $0.494B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.458B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.457B 26.95
GlycoMimetics (GLYC) United States $0.452B 0.00
Odonate Therapeutics (ODT) United States $0.437B 0.00
ArQule (ARQL) United States $0.401B 0.00
CASI Pharmaceuticals (CASI) United States $0.375B 0.00
Tyme Technologies (TYME) United States $0.371B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.367B 0.00
Majesco Entertainment (PTE) United States $0.359B 0.00
Xeris Pharmaceuticals (XERS) United States $0.358B 0.00
Akebia Therapeutics (AKBA) United States $0.350B 0.00
KalVista Pharmaceuticals (KALV) United States $0.337B 0.00
Concert Pharmaceuticals (CNCE) United States $0.330B 0.00
Lannett Co Inc (LCI) United States $0.306B 2.65
OptiNose (OPTN) United States $0.290B 0.00
Dermira (DERM) United States $0.286B 0.00
Aclaris Therapeutics (ACRS) United States $0.283B 0.00
Minerva Neurosciences (NERV) United States $0.278B 0.00
Depomed (ASRT) United States $0.272B 10.12
Verrica Pharmaceuticals (VRCA) United States $0.269B 0.00
Mast Therapeutics (SVRA) United States $0.265B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.264B 0.00
IMV INC (IMV) Canada $0.263B 0.00
Translate Bio (TBIO) United States $0.257B 0.00
Tapimmune (MRKR) United States $0.257B 0.00
Aldeyra Therapeutics (ALDX) United States $0.244B 0.00
Opexa Therapeutics (ACER) United States $0.231B 0.00
Dova Pharmaceuticals (DOVA) United States $0.225B 0.00
Affimed (AFMD) Germany $0.216B 0.00
TAIWAN LIPOSOME (TLC) Taiwan $0.210B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.210B 0.00
Aratana Therapeutics (PETX) United States $0.205B 0.00
MEI Pharma (MEIP) United States $0.203B 0.00
Aquestive Therapeutics (AQST) United States $0.192B 0.00
Galectin Therapeutics (GALT) United States $0.188B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.177B 0.00
Zafgen (ZFGN) United States $0.176B 0.00
Recro Pharma (REPH) United States $0.168B 0.00
Molecular Templates (MTEM) United States $0.166B 0.00
Ocular Therapeutix (OCUL) United States $0.165B 0.00
Rafael Holdings (RFL) United States $0.164B 0.00
Calithera Biosciences (CALA) United States $0.163B 0.00
Jounce Therapeutics (JNCE) United States $0.161B 0.00
Nature's Sunshine Products (NATR) United States $0.152B 0.00
Redhill Biopharma (RDHL) Israel $0.150B 0.00
Neon Therapeutics (NTGN) United States $0.147B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.145B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.145B 0.00
Ardelyx (ARDX) United States $0.145B 0.00
Adherex Technologies (FENC) United States $0.142B 0.00
Oasmia Pharmaceutical AB (OASM) Sweden $0.141B 0.00
ElectroCore (ECOR) United States $0.139B 0.00
Marinus Pharmaceuticals (MRNS) United States $0.137B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.136B 0.00
MediWound (MDWD) Israel $0.122B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.119B 0.00
Zomedica Pharmaceuticals (ZOM) United States $0.115B 0.00
Champions Oncology (CSBR) United States $0.112B 0.00
Matinas Biopharma Holdings (MTNB) United States $0.111B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.108B 0.00
DURECT (DRRX) United States $0.102B 0.00
ProNAi Therapeutics (SRRA) Canada $0.101B 0.00
Aptorum Group (APM) China $0.099B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.090B 0.00
Natural Alternatives (NAII) United States $0.082B 8.12
Nivalis Therapeutics (ALPN) United States $0.082B 0.00
Iterum Therapeutics (ITRM) Ireland $0.081B 0.00
Cardiome Pharma (CORV) Canada $0.077B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.076B 0.00
Infinity Pharmaceuticals (INFI) United States $0.075B 0.00
CTI BioPharma (CTIC) United States $0.074B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.071B 0.00
Neos Therapeutics (NEOS) United States $0.069B 0.00
KemPharm (KMPH) United States $0.067B 0.00
Immune Design (IMDZ) United States $0.066B 0.00
Achaogen (AKAO) United States $0.064B 0.00
Avenue Therapeutics (ATXI) United States $0.064B 0.00
BioLineRx (BLRX) Israel $0.064B 0.00
Otonomy (OTIC) United States $0.062B 0.00
Synergy Pharmaceuticals (SGYP) United States $0.059B 0.00
Melinta Therapeutics (MLNT) United States $0.057B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.055B 0.00
Genocea Biosciences (GNCA) United States $0.054B 0.00
Forward Pharma (FWP) Denmark $0.052B 0.00
Ampio Pharmaceuticals (AMPE) United States $0.051B 0.00
Actinium Pharmaceuticals (ATNM) United States $0.051B 0.00
Mannatechorporated (MTEX) United States $0.046B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.044B 0.00
ContraFect (CFRX) United States $0.042B 0.00
SCYNEXIS (SCYX) United States $0.038B 0.00
Capnia (SLNO) United States $0.037B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.035B 0.00
ProPhase Labs (PRPH) United States $0.035B 0.00
Lipocine (LPCN) United States $0.034B 0.00
Novan (NOVN) United States $0.034B 0.00
Heat Biologics (HTBX) United States $0.032B 0.00
IsoRay (ISR) United States $0.026B 0.00
Can-Fite Biopharma (CANF) Israel $0.025B 0.00
Trillium Therapeutics (TRIL) Canada $0.025B 0.00
PharmAthene (ALT) United States $0.024B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.024B 0.00
ESSA Pharma (EPIX) Canada $0.024B 0.00
Tokai Pharmaceuticals (NVUS) United States $0.022B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.020B 0.00
Citius Pharmaceuticals (CTXR) United States $0.020B 0.00
Biomerica (BMRA) United States $0.019B 0.00
Cyanotech (CYAN) United States $0.019B 0.00
Pain Therapeutics (PTIE) United States $0.019B 0.00
NovaBay Pharmaceuticals (NBY) United States $0.018B 0.00
Xenetic Biosciences (XBIO) United States $0.018B 0.00
NanoViricides (NNVC) United States $0.018B 0.00
Jaguar Animal Health (JAGX) United States $0.017B 0.00
HANCOCK JAFFE (HJLI) United States $0.017B 0.00
Auris Medical Holding AG (EARS) Switzerland $0.016B 0.00
Aviragen Therapeutics (VXRT) United States $0.015B 0.00
CollPlant Holdings Sponsored ADR (CLGN) Israel $0.015B 0.00
Onconova Therapeutics (ONTX) United States $0.013B 0.00
Shineco (TYHT) China $0.013B 1.46
Skyline Medical (AIPT) United States $0.011B 0.00
DelMar Pharmaceuticals (DMPI) Canada $0.010B 0.00
Regulus Therapeutics (RGLS) United States $0.010B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.010B 0.00
OncoGenex Pharmaceuticals (ACHV) United States $0.010B 0.00
Apricus Biosciences (APRI) United States $0.008B 0.00
Ohr Pharmaceuticals (OHRP) United States $0.007B 0.00
Aradigm (ARDM) United States $0.006B 0.00
RXi Pharmaceuticals (PHIO) United States $0.006B 0.00
Midatech Pharma (MTP) United Kingdom $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Ritter Pharmaceuticals (RTTR) United States $0.004B 0.00
Bio Blast Pharma (ORPN) Israel $0.004B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.003B 0.00
Intellipharmaceutics (IPCI) Canada $0.003B 0.00
Bio-Path Holdings (BPTH) United States $0.002B 0.00
Advanced Accelerator Applications (AAAP) France $0.000B 0.00
AGEX THERAPEUTC (AGE) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00